291 related articles for article (PubMed ID: 18339206)
21. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
22. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.
Gillick K; Pollpeter D; Phalora P; Kim EY; Wolinsky SM; Malim MH
J Virol; 2013 Feb; 87(3):1508-17. PubMed ID: 23152537
[TBL] [Abstract][Full Text] [Related]
23. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
[TBL] [Abstract][Full Text] [Related]
24. Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.
Münk C; Jensen BE; Zielonka J; Häussinger D; Kamp C
Viruses; 2012 Nov; 4(11):3132-61. PubMed ID: 23202519
[TBL] [Abstract][Full Text] [Related]
25. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.
Sadler HA; Stenglein MD; Harris RS; Mansky LM
J Virol; 2010 Jul; 84(14):7396-404. PubMed ID: 20463080
[TBL] [Abstract][Full Text] [Related]
26. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
27. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.
Chen G; He Z; Wang T; Xu R; Yu XF
J Virol; 2009 Sep; 83(17):8674-82. PubMed ID: 19535450
[TBL] [Abstract][Full Text] [Related]
28. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.
Ara A; Love RP; Chelico L
PLoS Pathog; 2014 Mar; 10(3):e1004024. PubMed ID: 24651717
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 Vif, APOBEC, and intrinsic immunity.
Goila-Gaur R; Strebel K
Retrovirology; 2008 Jun; 5():51. PubMed ID: 18577210
[TBL] [Abstract][Full Text] [Related]
30. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
Liddament MT; Brown WL; Schumacher AJ; Harris RS
Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
[TBL] [Abstract][Full Text] [Related]
31. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
Pery E; Rajendran KS; Brazier AJ; Gabuzda D
J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
[TBL] [Abstract][Full Text] [Related]
32. HIV restriction by APOBEC3 in humanized mice.
Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
[TBL] [Abstract][Full Text] [Related]
33. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
34. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
Siu KK; Sultana A; Azimi FC; Lee JE
Nat Commun; 2013; 4():2593. PubMed ID: 24185281
[TBL] [Abstract][Full Text] [Related]
35. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.
Zhang W; Chen G; Niewiadomska AM; Xu R; Yu XF
PLoS One; 2008; 3(12):e3963. PubMed ID: 19088851
[TBL] [Abstract][Full Text] [Related]
36. High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
Bertine M; Charpentier C; Visseaux B; Storto A; Collin G; Larrouy L; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
AIDS; 2015 Apr; 29(7):779-84. PubMed ID: 25985400
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
[TBL] [Abstract][Full Text] [Related]
38. Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.
Nagao T; Yamashita T; Miyake A; Uchiyama T; Nomaguchi M; Adachi A
J Med Invest; 2010 Feb; 57(1-2):89-94. PubMed ID: 20299747
[TBL] [Abstract][Full Text] [Related]
39. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
Zheng YH; Irwin D; Kurosu T; Tokunaga K; Sata T; Peterlin BM
J Virol; 2004 Jun; 78(11):6073-6. PubMed ID: 15141007
[TBL] [Abstract][Full Text] [Related]
40. Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice.
Sato K; Izumi T; Misawa N; Kobayashi T; Yamashita Y; Ohmichi M; Ito M; Takaori-Kondo A; Koyanagi Y
J Virol; 2010 Sep; 84(18):9546-56. PubMed ID: 20610708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]